Dipeptidyl peptidase IV, aminopeptidase N and DPIV/APN-like proteases in cerebral ischemia by Röhnert, Peter et al.
RESEARCH Open Access
Dipeptidyl peptidase IV, aminopeptidase N and
DPIV/APN-like proteases in cerebral ischemia
Peter Röhnert
1,2, Werner Schmidt
1,3, Patrick Emmerlich
1, Alexander Goihl
4, Sabine Wrenger
4, Ute Bank
5,
Karsten Nordhoff
1,5, Michael Täger
5, Siegfried Ansorge
5, Dirk Reinhold
4 and Frank Striggow
1,3*
Abstract
Background: Cerebral inflammation is a hallmark of neuronal degeneration. Dipeptidyl peptidase IV, aminopeptidase N
as well as the dipeptidyl peptidases II, 8 and 9 and cytosolic alanyl-aminopeptidase are involved in the regulation of
autoimmunity and inflammation. We studied the expression, localisation and activity patterns of these proteases after
endothelin-induced occlusion of the middle cerebral artery in rats, a model of transient and unilateral cerebral ischemia.
Methods: Male Sprague-Dawley rats were used. RT-PCR, immunohistochemistry and protease activity assays were
performed at different time points, lasting from 2 h to 7 days after cerebral ischemia. The effect of protease
inhibitors on ischemia-dependent infarct volumes was quantified 7 days post middle cerebral artery occlusion.
Statistical analysis was conducted using the t-test.
Results: Qualitative RT-PCR revealed these proteases in ipsilateral and contralateral cortices. Dipeptidyl peptidase II
and aminopeptidase N were up-regulated ipsilaterally from 6 h to 7 days post ischemia, whereas dipeptidyl
peptidase 9 and cytosolic alanyl-aminopeptidase were transiently down-regulated at day 3. Dipeptidyl peptidase 8
and aminopeptidase N immunoreactivities were detected in cortical neurons of the contralateral hemisphere. At
the same time point, dipeptidyl peptidase IV, 8 and aminopeptidase N were identified in activated microglia and
macrophages in the ipsilateral cortex. Seven days post artery occlusion, dipeptidyl peptidase IV immunoreactivity
was found in the perikarya of surviving cortical neurons of the ipsilateral hemisphere, whereas their nuclei were
dipeptidyl peptidase 8- and amino peptidase N-positive. At the same time point, dipeptidyl peptidase IV, 8 and
aminopeptidase N were targeted in astroglial cells. Total dipeptidyl peptidase IV, 8 and 9 activities remained
constant in both hemispheres until day 3 post experimental ischemia, but were increased (+165%) in the ipsilateral
cortex at day 7. In parallel, aminopeptidase N and cytosolic alanyl-aminopeptidase activities remained unchanged.
Conclusions: Distinct expression, localization and activity patterns of proline- and alanine-specific proteases
indicate their involvement in ischemia-triggered inflammation and neurodegeneration. Consistently, IPC1755, a
non-selective protease inhibitor, revealed a significant reduction of cortical lesions after transient cerebral ischemia
and may suggest dipeptidyl peptidase IV, aminopeptidase N and proteases with similar substrate specificity as
potentially therapy-relevant targets.
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Background
Focal cerebral ischemia is accompanied by marked inflam-
matory reactions in the affected brain regions, initiated by
microglia and astrocytes activation and the generation of
inflammatory mediators such as pro-inflammatory
cytokines and free oxygen radicals [1,2]. Moreover, during
focal cerebral ischemia, the local disruption of the blood
brain barrier leads to an invasion of reactive polymorpho-
nuclear neutrophils from the periphery into the brain
[3-5]. In addition to the breakdown of oxygen und sub-
strate supply due to vessel occlusion, invading immune
competent cells and the release of neurotoxic mediators
appear to be involved in the acceleration of neuronal cell
damage [6]. The activation of microglia/macrophages and
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ischemic area is reported to maintain for hours and days
after the initial ischemic insult [7]. Therefore, anti-inflam-
matory treatments of the ischemic brain may constitute a
therapeutic option to target delayed pathophysiological
processes and to manage neuronal degeneration and cere-
bral damage.
Peptidases like dipeptidyl peptidase IV (DPIV, CD26,
E.C. 3.4.14.5) and aminopeptidase N (APN, CD13, E.C.
3.4.11.2) are known to regulate a variety of biological
processes related to inflammation such as T cell activa-
tion, immune responses and inflammation-related dis-
eases [8-11]. DPIV, a 110 kD type II transmembrane
glycoprotein, identical with the T cell antigen CD26,
belongs to the group of post-proline dipeptidyl amino-
peptidases, consisting of five DPIV gene family pro-
teases, i.e. DPIV, fibroblast activation protein (FAP),
DP8, DP9, and DPII (E.C.3.4.14.2) [10-13].
DPIV catalyzes the release of N-terminal dipeptides
from oligo- and polypeptides, preferentially with a pro-
line, hydroxyproline or, although with lower efficiency,
alanine in the penultimate position [8-11]. The unique
substrate specificity of DPIV and DPIV-like enzymes
underlies their key role in the catabolism of a number of
chemo- and cytokines, neuropeptides, immunopeptides
and peptide hormones containing a X-Pro or X-Ala
amino terminal sequence, e.g. CXCL12, substance P, neu-
ropeptide Y, peptide YY, enterostatine, glucose-depen-
dent insulinotropic polypeptide (GIP), and glucagon-like
peptide-1 (GLP-1) [14-16]. Recently, it has been shown
that an additional binding site in the central pore of
DPIV is responsible for the cellular effects of ligands of
this enzyme with respect to growth regulation and cyto-
kine production [17].
APN, identical with the myeloid linage antigen CD13, is
a 150 kD type II transmembrane metalloprotease. It
belongs to the family of zinc-dependent aminopeptidases,
found in different subcellular organelles, in the cytoplasm
and as integral membrane proteins. APN is responsible for
the hydrolysis of neutral amino acids from the N-terminus
of oligopeptides. The peptidase stops peptide hydrolysis, if
a proline appears in the second position of the N-terminal
sequence, thereby generating potentially DPIV-susceptible
substrates. This mechanism may underlie a co-operative
mode of action between APN and DPIV [18]. APN has
been shown to be involved in the degradation of several
neuropeptides, angiotensins, cytokines and immunomodu-
latory peptides. APN also contributes to extracellular
matrix degradation and antigen processing [18,19].
Recent evidence points also towards a role of the
APN-like peptidase cytosolic alanyl-aminopeptidase
(cAAP) in the immune response. Expression of cAAP
mRNA was identified in CD4+, CD8+, Th1, Th2 and
Treg (CD4+ CD25+) T cell subpopulations [20].
DPIV, APN and the DPIV- and APN-like peptidases
are constitutively expressed in different brain regions
[21-25], indicating an important role in brain physiol-
ogy. Furthermore, it has been postulated that this group
of peptidases might be involved in neurodegenerative
processes due to different acute CNS insults such as a
stroke or traumatic brain injury [26,27].
To further examine the function of DPIV, APN and/or
DPIV-/APN-like peptidases in ischemia-dependent neu-
rodegeneration, we have studied these target peptidases
in an in vivo model of transient, unilateral cerebral ische-
mia due to endothelin-induced occlusion of the middle
cerebral artery (eMCAO). Using RT-PCR and enzymatic
assays, we analyzed the temporal pattern of expression
and peptidase activity of dipeptidyl peptidase II (DPII),
DPIV, dipeptidyl peptidase 8 (DP8), dipeptidyl peptidase
9 (DP9), APN and cAAP in ipsilateral (infarct) and con-
tralateral (control) cortices after eMCAO and transient
cerebral ischemia. In addition, the cell-type-specific loca-
lization patterns of DPIV, DP8 and APN in neurons,
astroglia, immune-reactive microglia cells and activated
macrophages were characterized by multi-labeling immu-
nohistochemistry at defined time points post eMCAO.
IPC1755, a non-selective inhibitor of DPIV/DPIV-like
and APN/cAAP protease activities, was able to decrease
cortical, eMCAO-induced lesion sizes. This effect was
also observed, if the compound was applied exclusively
post insult. In addition, distinct expression, localization
and activity patterns of DPIV, APN and DPIV-/APN-like
proteases indicate a crucial role of these targets in ische-
mia-induced inflammation and neurodegeneration.
Hence, DPIV and/or APN inhibitors may provide a basis
for the design of new and more efficient therapeutic stra-
tegies against the deleterious consequences of cerebral
ischemia.
Results
mRNA expression of DPII, DPIV, DP8, DP9, APN and cAAP
at different time points after eMCAO
Sprague-Dawley rats were exposed to a transient focal
cerebral ischemia due to eMCAO. 2 h, 6 h, 24 h, 3 d, and
7 d post eMCAO, cortices of the affected ipsilateral
hemisphere and the non-ischemic contralateral side were
separately collected and analyzed by qualitative RT-PCR.
Contralateral cortical tissue probes were used as internal
controls. Data obtained from contralateral, non-ischemic
cortices were similar to those using the corresponding
brain area of untreated or sham-operated adult rat brains,
not exposed to eMCAO (not shown). As shown in Figure
1, all peptidases considered in here were expressed in
both hemispheres. Nevertheless, we found increased
levels of DPII and APN mRNA expression in the ipsilat-
eral (ischemic) hemisphere, lasting from 6 hours to day 7
post eMCAO. In contrast, mRNA expression of DP9 was
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reduced mRNA content was also observed for cAAP at
day 3 after eMCAO. DPIV and DP8 mRNA levels
remained constant in both hemispheres at all time points
analyzed (Figure 1).
Immunohistochemical detection of DPIV, DP8 and APN
after eMCAO
In order to characterize the cellular localization of
DPIV, DP8 and APN after eMCAO, we performed a
multi-labeling immunohistochemistry approach using
protease-specific antibodies and cell-specific markers for
neurons, astroglia, immune-reactive microglia cells or
activated macrophages at defined time points post
eMCAO.
Unilateral ischemic brain damage induced by eMCAO
caused an infarction in the lateral parts of the frontal cor-
tex extending through the parietal and insular cortex ros-
trally and through temporal and occipital cortex caudally.
In addition, there was evidence of infarction within dorso-
lateral portions of the caudate nucleus. To analyze the
localisation of DPIV, DP8 and APN, the lateral part of the
frontal cortex ipsilateral to the infarct area including the
penumbra was selected. Corresponding cortical areas of
the contralateral hemisphere were chosen as internal
control.
In the non-ischemic, contralateral cortex as well as in
other contralateral brain areas, DPIV immunoreactivity
was generally not observed (Figure 2A-D). DP8 (Figure
2E-H) and APN (Figure 2I-L) were co-localized with
NeuN immunoreactivity, demonstrating their constitu-
tive localisation in neurons of the contralateral cortex.
In the same brain area, DP8 and APN were not co-
labeled with GFAP immunoreactivity, a marker of astro-
glial cells, or IB4, specific for immunoreactive microglia
(not shown). Three days after eMCAO, DPIV was found
to be co-localized with IB4-positive microglia in the
infarct area of the ipsilateral cortex (Figure 3A). In par-
allel, DP8 and APN matched ED1-linked fluorescence of
reactive microglia/macrophages (Figure 3B, C). In addi-
tion, a small number of surviving, NeuN-positive neu-
rons in the infarct core of the ipsilateral cortex were co-
stained with DP8 and APN immunoreactivity, whereas
DPIV-positive neurons were not identified at day 3 (not
shown). Thus, DP8 and APN localization can be
addressed to the perikarya of surviving neurons in the
ipsilateral cortex.
Seven days after the induction of eMCAO, surviving,
NeuN-positive neurons in the ischemic cortical penum-
bra remained DP8- and APN-positive (Figure 3E,F).
Furthermore, we were able to identify neuron-specific
DPIV immunoreactivity, tagged with Neurotrace, a mar-
ker of neuronal perikarya (Figure 3D). In parallel, DPIV,
DP8 and APN were also found to be co-stained with
GFAP immunoreactivity (Figure 3G-I), demonstrating
the presence of these proteases in astroglial cells. At day
DPII 
DPIV 
DP8 
DP9 
APN 
cAAP 
ß-Actin 
    2 h       6 h       24 h         3 d           7d
C        I        C        I        C        I        C        I         C        I 
Figure 1 Rat brain mRNA expression of DPII, DPIV, DP8, DP9, APN and cAAP after focal cerebral ischemia due to eMCAO. Protease and
b-actin mRNAs of ipsilateral (infarct, I) and corresponding contralateral (control, C) hemispheres are represented. Time points post eMCAO as
indicated. One representative of four independent experiments is shown.
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cence was not observed in microglia and macrophages
anymore (not shown).
DPIV/DPIV-like and APN/APN-like protease activities in
the brain
To determine the distribution of the distinct proteases of
interest in cerebral homogenates, we established an
enzyme activity competition assay utilizing selective
DPII, DPIV, DP8/9 or cAAP inhibitors. Based on this,
specific protease activities were calculated by a non-linear
regression analysis (see Methods for details).
Kinetic studies of DPIV and DPIV-like proteases
according to Michaelis-Menten were performed using
homogenates of contralateral (control) or ipsilateral
(infarct) cortices prepared from adult rats at different
time points after eMCAO. As shown in Figure 4A, DPIV/
DPIV-like activity remained unaffected and almost
equally distributed in both hemispheres until day 3 post
insult. However, maximum total DPIV/DPIV-like activity
(Vmax) was significantly increased (+165%) in the ipsilat-
eral cortex compared to the corresponding contralateral
cortex 7 days post eMCAO (p = 0.025, Figure 4A, B).
Vmax of DPIV/DPIV-like activity was 6.9 ± 1.5 nmol/
min/mg protein (n ± 5) and 2.6 ± 0.4 nmol/min/mg pro-
tein (n = 5) in the ipsilateral and contralateral cortex,
respectively. In contrast to Vmax, Michaelis-Menten con-
stants (Km) of protease-catalyzed substrate hydrolysis
remained unchanged in both hemispheres (ipsilateral:
Km =3 8 0±4 0 μM, n = 5; contralateral: Km = 330 ±
20μM, n = 5, Figure 4B).
Subsequently, we studied the fractional distribution of
DPII, DPIV and DP8/9 with respect to the total DPIV/
DPIV-like activity in contra- and ipsilateral cortices
from 2 h until 7 days post eMCAO. A small fraction of
DPIV/DPIV-like activity was continuously detectable in
adult cortical homogenates, including the contralateral
hemisphere, at all time points post eMCAO considered in
here. 2 h post eMCAO, DPII-specific activity was 34 ±
4.3% of total DPIV/DPIV-like activity in the ipsilateral
(infarct) cortex versus 39 ± 3.3% contralateral (Figure 4C).
In parallel, DP8/9 activity was 42 ± 5.6% ipsilateral versus
49 ± 3.7% contralateral. At the same time point, a small,
but similar degree of DPIV activity was detectable ipsilat-
eral (8.5 ± 5.3%) and contralateral (11 ± 5.8%, Figure 4C).
At day 7 post eMCAO, the fractional distribution of dif-
ferent DPIV/DPIV-like activities was altered in the follow-
ing manner. DP8/9 activity was decreased to 25 ± 5.0%
ipsilateral versus 38 ± 4.5% contralateral, DPII activity was
slightly increased to 59 ± 4.6% ipsilateral and 46 ± 5.0%
contralateral, whereas fractional DPIV activity remained
rather unchanged (11 ± 1.7%, ipsilateral versus 8 ± 2.2%,
contralateral, Figure 4C). At the same time point, eMCAO
induced a significant Vmax increase of DPII-specific activity
(+237%) in ipsilateral cortices in comparison to the con-
tralateral control tissue (p = 0.0001, Figure 4D, E). In par-
allel, we determined a rise of Vmax of DPIV activity
(+262%) in ipsilateral cortices (p = 0.0004, Figure 4D, E).
Similar to DPIV and DPIV-like proteases, the Michaelis-
Menten-kinetics of APN and cAAP activity were studied
in homogenates of ipsilateral (infarct) and contralateral
(control) cortices after eMCAO. Instead of Gly-Pro-pNA,
the hydrolysis of Ala-pNA was analyzed. From 2 h to day
7 post eMCAO, total activity of APN and cAAP remained
unaffected (Figure 5A). Furthermore, ipsilateral and con-
tralateral cortex homogenates were characterized by
roughly equal Km (ipsilateral: Km =1 6 0 μM ± 0.004μM,
n = 5; contralateral: Km =1 6 0 μM ± 0.019μM, n = 5) and
similar Vmax values (ipsilateral: 6.2 ± 2.1 nmol/min/mg
protein, n = 5; contralateral: 5.5 ± 1.3 nmol/min/mg
Figure 2 Immunohistochemical localization of DPIV, DP8 and APN in contralateral cortices 7 days after eMCAO. Co-stainings were
performed using the neuronal markers Neurotrace (A) or NeuN (F, J). DPIV (B), DP8 (E) and APN (I) -linked fluorescences were visualized by
confocal laser scan microscopy. DAPI was used to stain cell nuclei (C, G, K, blue fluorescence). Furthermore, merged fluorescence images are
shown (D, H, L). Contralateral hemispheres were not exposed to eMCAO. Note, DPIV immunostaining was not found under these conditions (see
B). Similar results were obtained in untreated or sham-operated animals as well as 3 days after eMCAO in the contralateral cortex (not shown).
Scale bars = 100 μm.
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selective cAAP inhibitor PAQ22 [20,28], revealed constant
fractional activities of APN and cAAP in both hemispheres
(Figure 5C).
Effects of the non-selective DPIV and APN inhibitor
IPC1755, and selective inhibition of DPIV, DPII or DP8/9
on ipsilateral lesion sizes after eMCAO
In order to address the question, whether dual inhibi-
tion of DPIV- and APN-like protease activities supports
neuronal cell survival after transient cerebral ischemia,
IPC1755, an inhibitor of DPIV/DPIV-like and APN/
cAAP protease activity (Figure 6, see Materials for refer-
ence and protease-specific IC50 values), was adminis-
tered icv ipsilateral to eMCAO. 7 days post insult, the
infarct volume of vehicle (PBS)-treated control animals
was 100.9 ± 8.9 mm
3 in the ipsilateral cortex, and 22.6
±2 . 4m m
3 in the ipsilateral striatum (Figure 7A, C, col-
umn a). In the first series, IPC1755 (10 μM) was given
in parallel to the induction of eMCAO and in addition,
6 h and 24 h post insult. Under these conditions,
IPC1755 reduced the eMCAO-induced infarct volume
Figure 3 Immunohistochemical staining of DPIV, DP8 and APN in ipsilateral cortices at different time points after eMCAO. Confocal
fluorescence images were captured either 3 (A-C) or 7 days (D-I) post eMCAO. DAPI was used to stain cell nuclei (A-I, blue fluorescence). At day
3, the time point when microglia activation peaked, DPIV (A, green florescence) was co-stained with IB4 (red) to indentify immunoreactive
microglia, whereas DP8 (B, green) and APN (C, red) were co-labeled with ED1 (B, red; C, green), a marker of reactive macrophages. Co-
localization of DPIV, DP8 or APN labeling with IB4 (activated microglia) and ED1 (active microglia/macrophages), respectively, is visualized by
merged fluorescence signals (A-C, yellow, arrows). At day 7, DPIV (D, G, red), DP8 (E, H, green) and APN (F, I, green) were co-stained with
Neurotrace targeting neuronal prerikarya (D, green) or NeuN, labeling neuronal nuclei (E, F, red). Alternatively, DPIV, DP8 and APN were co-
labeled with GFAP, expressed in astroglial cells (G, green; H and I, red). Co-localization of each protease with the respective cell markers is seen
(D-I, yellow, arrows). Scale bars = 10 μm (A-F) and 20 μm (G-I).
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cle-treated control animals (Figure 7B, C, column b).
We still observed a significant reduction of eMCAO-
induced lesion sizes by 33,0 ± 7.9%, when the first
IPC1755 administration was delayed until 2 h post
eMCAO (Figure 7C, column c). An IPC1755-dependent
effect on lesion sizes was not observed, if IPC1755 was
exclusively applied 6 and 24 h post eMCAO (107.5 ±
12.8%, Figure 7C, column d). These findings reveal a
potential, therapy-relevant time window between 2 and
6 h post ischemia. In general, IPC1755 did not affect
striatal lesion sizes (Figure 7C, columns b-d).
In the next series of experiments, we have investigated
the influence of subtype-specific inhibition of DPIV,
DPII or DP8/9 on neuronal cell survival after eMCAO.
In analogy to IPC1755, each inhibitor (see Materials for
details) was administered icv in parallel to the induction
o fe M C A Oa sw e l la s6ha n d2 4hp o s ti n s u l t( f . c .
10 μM for each injection). 7 days post insult, the infarct
volumes of vehicle (PBS)-treated control animals were
Figure 4 DPIV and DPIV-like protease activities after transient cerebral ischemia.( A )R e l a t i v eV max of DPIV/DPIV-like activity in adult rat
cortices of ipsilateral (infarct, black bars) or contralateral (control, gray bars) hemispheres at different time points after eMCAO. A pronounced
Vmax increase in the ipsilateral cortex compared to the contralateral cortex was detectable 7 day post insult (+165%, for details, see text). At
earlier time points, differences between both hemispheres were not found (n = 5). (B) Michaelis-Menten kinetics of total DPIV/DPIV-like activity in
infarct (solid line) and control cortices (dashed line) 7 days post eMCAO. Ipsilateral and contralateral cortices revealed similar Km values, i.e.
ipsilateral: Km = 380 ± 40μM; n = 5; contralateral: Km = 330 ± 20μM; n = 5, whereas Vmax differed significantly (p = 0.025, t-test), i.e. ipsilateral: 6.9
± 1.5 nmol/min/mg protein, n = 5; contralateral: 2.6 ± 0.4 nmol/min/mg protein, n = 5. (C) Relative fractional contribution of DPII, DP8/9 and
DPIV activity to total DPIV-like protease activity (Gly-Pro-pNA cleavage) in the ipsilateral (infarct, left bar group) and contralateral (control, right
bar group) cortex at different time points after eMCAO (pH 7.5). (D) Vmax of DPII, DPIV and DP8/9 in the ipsilateral and contralateral cortex. (E)
Relative activities of DPII, DPIV or DP8/9 in ipsilateral (black bars) or contralateral control (gray bars) cortices 7 days post eMCAO. Data are means
± SD from 5 independent experiments. *p = 0.0001; **p = 0.0004 (t-test).
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Page 6 of 15Figure 5 APN and cAAP protease activities after transient cerebral ischemia. (A) Relative Vmax of APN and cAAP activity in adult rat cortices
of ipsilateral (infarct, black bars) or contralateral (control, gray bars) hemispheres at different time points after eMCAO. (B) Michaelis-Menten
kinetics of total APN/cAAP activity in infarct (solid line) and control cortices (dashed line) at day 7 after eMCAO. Ipsilateral and contralateral
cortices were characterized by roughly equal Km (infarct: Km = 160μM ± 0.004μM, n = 5; contralateral: Km = 160μM ± 0.019μM, n = 5) and similar
Vmax values (infarct: 6.2 ± 2.1 nmol/min/mg protein, n = 5; contralateral: 5.5 ± 1.3 nmol/min/mg protein, n = 5). (C) Relative fractional
contribution of APN (black) and cAAP (white) activity to total aminopeptidase activity (Ala-pNA hydrolysis) in the ipsilateral (infarct, left bar
group) and contralateral (control, right bar group) hemisphere at different time points after eMCAO (pH 7.5).
Figure 6 Chemical structure of IPC1755.
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3 and 29.9 ± 3.1 mm
3 in the ipsilateral
cortex and striatum, respectively (Figure 7C, column e).
According to the above application protocol, only sita-
gliptin, a selective DPIV inhibitor, was able to reduce
the cortical infarct size by 21.1 ± 5.8% compared to
vehicle (Figure 7C, column e, f). This neuroprotective
effect of sitagliptin was smaller than the effect of the
non-selective protease inhibitor IPC1755 using the same
experimental conditions (48.8 ± 7.9%, compare Figure
7 C ,c o l u m na ,b ,e ,f ) .I nc o n t r a s tt os i t a g l i p t i n ,s e l e c t i v e
DPII or DP8/9 inhibition did not decrease eMCAO-
induced infarct volumes in ipsilateral cortices (Figure 7C,
column e, g, h). Similar to IPC1755, neither sitagliptin
nor selective DPII or DP8/9 inhibition affected striatal
lesion sizes (Figure 7C, columns a, b, e-h).
Discussion
DPIV, APN as well as DPIV- and APN-like proteases are
known to regulate T cell activation and/or the synthesis
and the release of certain cytokines, chemokines and
neurotransmitters. Moreover, inhibitors of DPIV and
APN have been frequently considered as potential candi-
dates for the therapy of autoimmune diseases and post-
transplantation immune reactivity. Behind this, ischemia-
induced neuronal cell degeneration and cerebral damage,
for instance due to a stroke, traumatic brain injury or
Figure 7 Effect of non-selective or selective inhibition of DPIV and DPIV-like proteases on eMCAO-induced neurodegeneration. Nissl-
stained brain sections show cortical and striatal infarct areas 7 days post eMCAO, marked with black lines of one (A) vehicle- or (B) IPC1755-
treated animal at anterior-posterior level Bregma: 0.40 mm to 0.80 mm. (A) and (B) illustrate infarct areas of individual brain sections
corresponding to infarct volumes given in C, columns a and b, respectively. Scale bars = 1 mm (C) Morphometrical analysis of cortical and
striatal infarct volumes. Equal volumes (2 μl) of vehicle (column a, e) or IPC1755, a non-selective inhibitor of DPIV/DPIV-like and APN/cAAP
protease activity (columns b-d) or the specific DPIV inhibitor sitagliptin (column f) or selective inhibitors of DPII (column g) and DP8/9 (column
h) were injected icv (f.c. 10 μM) according to the following time schemes. Columns a, b, e-h: first injection in parallel to eMCAO and
subsequently, 6 and 24 h after eMCAO; column c: first injection 2 h after eMCAO and then, 6 and 24 h post eMCAO or column d: first injection
6 h and second injection 24 h after eMCAO. Infarct volumes were analyzed 7 days post eMCAO. Cortical (1) and striatal (2) lesion volumes of
ipsilateral rat brain hemispheres were quantified individually. Data are given as relative values (% of control damage of vehicle-treated animals).
In general, cortical infarct volumes of vehicle-treated control animals were set to 100% (column a, e). See Results for corresponding absolute
infarct sizes (mm
3). Data are given as means ± S.E.M., n = 8 - 12 animals per treatment group ***p ≤ 0.001 and *p ≤ 0.05, compared to vehicle-
treated animals, t-test.
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brain which promote a further, secondary brain damage
[2]. Based on this deleterious cascade, the reduction and
control of cerebral inflammation after cerebral ischemia
can be considered as valid therapeutic option to improve
neuronal cell survival and the clinical outcome of these
patients.
Although mRNA expression of DPIV and DPIV-like
proteases was previously reported in the brain [21-25],
the regulation of these targets in acute, cerebral ische-
mia-triggered neuronal degeneration and inflammation
has remained widely unknown.
As reported here, mRNA expression of DPIV, DPII,
DP8, DP9, APN and cAAP is localized in ipsilateral and
contralateral brain hemispheres. After transient and uni-
lateral cerebral ischemia, protease-specific mRNA
expression was differentially affected in the ipsilateral
cortex. DPII and APN were continuously up-regulated
from 6 h to 7 days post eMCAO. In contrast, DP9 and
cAAP were transiently down-regulated, whereas DPIV
remained unchanged.
Protease-specific mRNA expression and protein localiza-
tion patterns did not overlap entirely. In particular, DPIV-
specific immunoreactivity was generally not detectable in
brains of control animals and in the contralateral hemi-
sphere after unilateral induction of eMCAO. Contrarily,
DP8 and APN immunoreactivities were localized in con-
tralateral cortices, i.e. in nuclei of intact cortical neurons.
Notably, the appearance of DPIV-linked immunoreac-
tivity in the rat brain was ischemia-dependent and exclu-
sively restricted to the ipsilateral hemisphere, arising first
in immune reactive microglia (3 d post eMCAO) and
subsequently spreading to activated astroglial cells and
surviving neurons (7 d post eMCAO). Despite constantly
detectable DPIV mRNA levels in post-ischemic and non-
ischemic cortices, immunoreactivity of this protease was
ischemia-dependent. In the ipsilateral cortex, also DP8
and APN immunoreactivties were affected by eMCAO,
i.e. with a similar temporal, but distinct spatial pattern.
Both proteases were targeted in immune-reactive macro-
phages and astroglia 3 and 7 days post eMCAO, respec-
tively. These findings suggest the involvement of DPIV,
DP8 and APN in the regulation of immune-competent
cells and intracerebral inflammation in response to cere-
bral ischemia. The pattern of mRNA expression and
immunohistochemical detection of DP8 was similar to
DPIV, i.e. we found a cell-type specific and time-depen-
dent detection of DP8 in reactive microglia/macrophages
(3 days post eMCAO) and astroglia (7 days post
eMCAO) without changes in mRNA expression.
In addition, surviving neurons in the ipsilateral, ische-
mia-exposed cortex were characterized by DPIV-positive
perikarya and DP8- and APN-positive nuclei 7 days post
eMCAO. These results indicate a role of these proteases
in ischemia-dependent neuronal signalling cascades.
Nevertheless, it remains to be clarified, whether their
appearance is linked to deleterious or beneficial effects in
neurons surviving the eMCAO-induced ischemia.
In adult rat brains, functionally active DPII, DP8/9,
APN and cAAP were identified in cerebral cortices of
both brain hemispheres, independent of the exposure to
eMCAO. These findings were consistent with our RT-
PCR and immunohistochemistry results. Low levels of
DPIV activity were found also in contralateral cortices of
adult rats. The latter finding was in line with the expres-
sion pattern of DPIV, but was not supported by
immunohistochemistry.
Seven days after the induction of eMCAO, a significant
increase of DPIV and DPIV-like activity, i.e. Vmax,w a s
discovered. As revealed by fractional protease activity
studies, DPII, DPIV and, to a smaller extent, DP8/9 con-
tributed to the ischemia-triggered rise of protease activity
in ipsilateral cortices 7 days post eMCAO. Over the first
7 days after eMCAO, the ratio of DPII/DP8/9 activity
increased continuously in the ipsilateral cortex, but
remained constant contralateral. In general, protease
activities of APN and cAAP were not altered over the
first 7 days post eMCAO. Rather, Vmax and Km values of
both enzymes as well as the ratio of fractional APN and
cAAP activities remained constant.
Ischemia-dependent activity patterns of DPIV- and
DPIV-like proteases were at least partly mirrored by their
temporal expression pattern. For instance, the continuous
rise of DPII activity over the first 7 days post eMCAO was
coincident with the increase of DPII-specific mRNA
obtained in the qualitative RT-PCR analysis. Furthermore,
the decreasing contribution of DP8/9 to total DPIV-like
activity was roughly in line with constant or transiently
decreased mRNA levels of DP8 and DP9, respectively, in
the ipsilateral cortex. On the other hand, it remains
unclear, how eMCAO-independent activities of APN and
cAAP correspond to the up-regulation of APN and transi-
ently decreased cAAP mRNA levels in the ipsilateral
hemisphere.
Our findings suggest that DPII, DPIV, DP8 and DP9 as
well as APN and cAAP may be directly linked to the acti-
vation and proliferation of brain-innate immune-compe-
tent cells after eMCAO and a transient cerebral ischemia.
Conceivably, increased protease activities emerge at early
time points after ischemic insults. This study suggests that
DPIV- and APN-like protease immunoreactivities, except
DPIV itself, are mainly assigned to neuronal cells in unaf-
fected, healthy brain areas. In addition, increased activities
of DPIV and DPIV-like enzymes coincide with the vast
proliferation and activation of microglia and macrophages
around day 3 after eMCAO. Thus, increased protease
activity induced by glia activation may counteract the
decrease of neuronal proteases resulting from neuronal
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astroglia activation in the ipsilateral cortex at later time
points could underlie the significant increase in the sum
protease activity after eMCAO. Due to the decline of vital
neurons until day 3 post insult, a strongly decreased pro-
tease immunoreactivity of neurons was detected. In paral-
lel, there was a robust co-localisation of DPIV/APN
proteases with microglial markers. In the contralateral
hemisphere, microglia activation as well as co-staining of
DPIV, DP8 and APN and microglia markers was not
observed.
As known, neuronal degeneration lasts over the first
hours post ischemia, whereas microglia activation is
delayed and reaches its maximum around day 3 post
insult. Subsequently, the number of activated microglia
cells pulls back to nearly baseline values, but with conco-
mitant astroglia proliferation and activation. This delayed
activation pattern appears to be typical for ischemia-
induced brain damage [2]. The present study reveals now
that the temporal regulation of glia cell type proliferation
and activation is accompanied by the specific regulation
and activation of DPIV, APN and distinct DPIV- and
APN-like proteases. Notably, neuron-specific DPIV was
exclusively identified in surviving neurons at day 7 post
eMCAO. In addition, DPIV was a characteristic feature
of activated microglia, macrophages and astroglia in the
ipsilateral cortex 3 and 7 days post eMCAO, respectively.
A similar or even more pronounced pattern was obtained
with respect to DP8/9 and DPII. DPII as well as DP8/9-
specific protease activity were potently caused by glia
proliferation and activation within the first days post
eMCAO.
The involvement of DPIV, APN and DPIV-/APN-like
proteases in ischemia-triggered signaling cascades was
confirmed by the ability of the non-selective inhibitor of
DPIV and APN protease activity IPC1755 (10 μM) to
reduce cortical lesion sizes and to promote neuronal cell
survival after a transient focal ischemia due to eMCAO.
Based on the corresponding IC50 values of IPC1755,
DPIV (0.06 μM), APN (0.03 μM) and/or cAAP (0.02 μM),
rather than DPII (166 μM) or DP8/9 (85 μM), might serve
as its potential targets in cerebral ischemia. This assump-
tion was further supported by the finding that in contrast
to selective blockers of DPII or DP8/9, sitagliptin (10 μM),
a selective DPIV inhibitor, was also able to mediate neuro-
protection, although to a smaller extent than IPC1755.
Sitagliptin was the first DPIV inhibitor that was approved
for the treatment of diabetes mellitus type-2. DPIV inhibi-
tors mediate an anti-hyperglycemic effect by counteracting
the proteolytic cleavage of incretins such as glucagon-like
peptide-1 (GLP-1) and consequently, stimulate insulin and
suppress glucagon release [29]. DPIV is characterized by a
central pore that is crucially involved in the autosterical
regulation and substrate access to the active site of the
plasma membrane-bound protease [17]. Evidence for a
similar regulation of APN is given. Synthetic inhibitors of
membrane-bound DPIV able to suppress DNA synthesis
and cytokine production of immune cells are either (1)
ligands of a central pore binding site 2 nm apart from the
active site, thereby blocking substrate access to the active
site or (2) inhibitory ligands of the active site itself [17].
IPC1755 fits into the first paradigm (Figure 8A), whereas
sitagliptin belongs to the second group of DPIV inhibitors
(Figure 8B). In here, we provide experimental evidence
suggesting that both modes of inhibition of membrane-
bound DPIV can mediate neuronal protection after cere-
bral ischemia. Blockage of substrate access to the active
site through the central pore of DPIV (by IPC1755) or
alternatively, inhibition of the active site itself (by sitaglip-
tin) were able to support neuronal survival after cerebral
ischemia. Neuroprotection may result from the inhibition
of brain-derived and peripheral immune cells circulating
in the brain and consequently, the repression of devastat-
ing cerebral inflammation and secondary brain damage. In
addition, DPIV inhibition may prevent the degradation of
neuroprotective and/or anti-inflammatory peptides (e.g.
neuropeptide Y, brain-derived neurotrophic factor and
transforming growth factor ß). In this context, DPIV, APN
and/or cAAP may act in a synergistic manner.
(1) Temporal protease activity profiles post eMCAO
and (2) given protease specificities of IPC1755 and sita-
gliptin implicate that early inhibition of membrane-
bound DPIV (by IPC1755 or sitagliptin), APN and/or
cAAP (by IPC1755) induces anti-inflammatory and neu-
roprotective effects in the penumbra surrounding the
infarct core and supports long-term neuronal survival
after cerebral ischemia.
Notably, IPC1755 mediated neuronal protection, even
if applied at delayed time points after eMCAO. A time
window of 2 to 6 h between cerebral ischemia and treat-
ment start might be appropriate for potential therapeutic
approaches. It is well established that severe cerebral
ischemia starts to trigger massive inflammation due to
microglial activation and leukocyte infiltration within a
few hours post insult. Four to six hours after ischemia,
astrocytes become hypertrophic while miccroglial cells
retract their processes and assume an amoeboid mor-
phology that is typical of activated microglia [30]. We
suggest that inhibition of DPIV, APN and/cAAP within a
narrow time window may reduce crucial inflammation
and protect vulnerable neurons within the ischemic
penumbra. Additional treatments with IPC1755, for
instance given 6 hour and 24 hour post ischemia, may
provide further support although being insufficient to
promote neuroprotection if given exclusively. Neverthe-
less, further studies are required to identify most suitable
drug application protocols for preventive and/or thera-
peutic intervention strategies.
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Taken together, this study suggests distinct inflamma-
tory regulator proteases as potentially important media-
tors of ischemia-induced neuronal cell death and
cerebral inflammation. This may imply new options to
fight the deleterious consequences of cerebral ischemia
and/or deregulated inflammation in the context of acute
and chronic neurodegeneration.
Methods
Animals
Studies were performed on male Sprague-Dawley rats
(250-280 g) obtained from Harlan Winkelmann (Borchen,
Germany). Animals were maintained under constant
environmental conditions with an ambient temperature of
21 ± 2°C and relative humidity of 40%. They were housed
with a 12-h light-dark cycle, food and water were given ad
libitum.
All animal experiments described in this study were in
accordance with the legal requirements of the German
Tierschutzgesetz from 1998. The study was approved by
the authorities of the State of Saxony-Anhalt (Landesver-
waltungsamt) and performed according to institutional
guidelines.
Materials
L-2,4-Diaminobutyrylpiperidinamide, a selective inhibitor
of DPII [31], was purchased from Merck/Calbiochem
(Darmstadt, Germany). (2S,3R)-2-(2-amino-3-methyl-1-
oxopentan-1-yl)-1,3-dihydro-2H-isoindole hydrochloride
as selective DP8/DP9 inhibitor and (2S)-2-[4-[[[[(2S)-1-
[(3R)-3-amino-4-(2,5-difluorophenyl)-1-oxobutyl]-2-pyrro-
lidinyl]carbonyl]amino]methyl]phenoxy]-3-methylbutanoic
acid, trifluoroacetate as a selective DPIV-inhibitor were
synthesized according to [32]. Sitagliptin ((R)-3-Amino-1-
[3-(trifluormethyl)- 5,6,7,8-tetrahydro[1,2,4]triazol[4,3-a]
pyrazin-7-yl]- 4-(2,4,5-trifluorphenyl)butan-1-on), a selec-
tive DPIV inhibitor was purchased from Merck Sharp &
Dohme (Pavia, Italy). Actinonin, an inhibitor of APN and
cAAP, was purchased from Sigma (Taufkirchen, Ger-
many), and PAQ-22, a specific inhibitor of cAAP, was
synthesized according to [28].
IPC1755 was synthesized by MOLISA (Magdeburg,
Germany). IPC1755 (25 mmol) was dissolved in dimethyl
sulfoxide (DMSO, Sigma-Aldrich, Germany) and diluted
with 0.1 M phosphate buffer saline (PBS, pH 7.4) to a
final stock concentration of 10 mmol/l. Sitagliptin, L-2,4-
Diaminobutyrylpiperidinamide (a selective DPII inhibi-
tor) or (2S,3R)-2-(2-amino-3-methyl-1-oxopentan-1-yl)-
1,3-dihydro-2H-isoindole hydrochloride (selective DP8/
9-inhibitor) were separately diluted with 0.1 M phosphate
buffer saline (PBS, pH 7.4) to a final stock concentration
of 10 mmol/l. Inhibitor-specific stock solutions (2 μL)
were administered intracerebroventricularly (icv)a td i f -
ferent time points after the induction of eMCAO (final
drug concentrations 10 μM). IPC1755 (Patent
EP09169269) is a non-selective DPIV and APN inhibitor
with the following values of protease-specific half maxi-
mal inhibitory concentrations (IC50): 0.06 μM( D P I V ) ,
0.03 μM( A P N ) ,0 . 0 2μM (cAAP), 166 μM (DPII) and 85
μM (DP8/9). IPC1755 suppressed the proliferation of
mononuclear cells (IC50 =3 6μM) and T cells (IC50 =3 4
μM).
All other chemicals were of highest available purity.
Induction of eMCAO
Procedures were designed such that experimental animals
do not suffer unnecessarily. eMCAO was performed
according to Sharkey and Butcher [33] with the following
modifications. Animals were anesthetized with halothane in
a mixture of nitrous oxide/oxygen (70:30) and maintained
with 2-3% halothane during the following procedures: rats
Figure 8 Inhibition of membrane-bound DPIV by IPC1755 and sitagliptin.( A )I P C 1 7 5 5( y e l l o w ,o r a n g ea nd blue marking) binds to the
central pore binding site 2 nm in front of the active site of DPIV. Consequently, the central pore becomes completely blocked. This is crucial,
because, in contrast to soluble DPIV, this pore remains the only substrate and inhibitor access route of the membrane-bound enzyme. In
contrast to soluble DPIV, alternative substrate access through the side pore of the protease (not shown) has been postulated to be restricted by
other membrane proteins, glycolipid-enriched domains and/or lipid rafts [17]. (A) Sitagliptin (orange) binds directly to the active site of DPIV and
is therefore able to inhibit both, membrane-bound and soluble DPIV.
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anesthetized via a nose cone. For the induction of eMCAO,
a burr hole (1 mm diameter) was drilled into the skull
(coordinates: anterior 0.50 mm from bregma, lateral 5.2
mm to satura sagittalis). After careful opening of the dura,
a 29-gauge cannula was lowered 7.5 mm below the dura
according to the rat brain atlas of Paxinos and Watson [34].
To induce eMCAO, rats received an injection of 60 pmol
of endothelin 1 (ED-1, Sigma-Aldrich) in 3 μlo f0 . 1M
phosphate-buffered saline, pH 7.4, over a time period of
5 min. After further 5 min, the cannula was slowly with-
drawn. Throughout the operation procedure, rats were
kept at 37 ± 0.5°C using a thermostatically controlled heat-
ing blanket attached to a rectal thermometer. The animals
were then placed under a heating lamp to maintain nor-
mothermia until recovery.
Preparation of total RNA
Cortical tissue probes from ipsilateral and contralateral
brain hemispheres were prepared separately at defined
time points after eMCAO and then pounded with a pes-
tle and mortar under liquid nitrogen to a fine powder.
After homogenization in TRIzol reagent (Invitrogen,
Darmstadt, Germany), 0.2 ml chloroform were added, the
samples were extensively shaken by hand and then incu-
bated at room temperature for 2 min. Subsequently, the
tissue suspensions were centrifuged for phase separation
at 12,000 × g at 4°C for 10 min. The upper RNA-contain-
ing aqueous phase was collected, mixed with the 0.7-fold
volume of isopropanol and incubated at room tempera-
ture for 10 min. The precipitated RNA was collected by
centrifugation with 12,000 × g at 4°C for 10 min. The
RNA was washed with 75% ethanol and again centrifuged
at 7,500 × g at 4°C for 5 min. The supernatant was care-
fully removed and the pellet air-dried at room tempera-
ture for 10 min. The total RNA was then resolved in 100
μl RNase-free water. The RNA concentration was deter-
mined by UV spectroscopy, using a GeneQuant spectro-
photometer (Amersham Biosciences, Freiburg,
Germany). RNA integrity was checked in agarose gels.
Reverse transcription of total RNA
After 5 min pre-incubation of 2.5 μg total RNA with ran-
dom hexanucleotides (Boehringer, Mannheim, Germany)
in a final concentration of 4 mM at 70°C, the supplied
avian myeloblastosis virus (AMV) reverse transcriptase
buffer, desoxynucleoside triphosphates in a final concen-
tration of 1 mM and 50 units of RNAsin ribonuclease
inhibitor (Promega, Mannheim, Deutschland) were
added. Samples were cooled down to 25°C before 20
units of AMV reverse transcriptase (Promega, Man-
nheim, Germany) were added yielding a final volume of
the reaction mixture of 20 μl. After 10 min at 25°C,
reverse transcription was performed at 42°C for 1 h. The
enzymatic reaction was stopped by a 10 min incubation
at 70°C.
PCR
PCR was carried out with 125 ng cDNA using a PCR-
Hot Start-Mix Y (PeqLab, Erlangen, Germany). The
reaction mixture (final volume 50 μl) contained 10 μM
of protease and rat-specific primers. The temperature
program was performed in a lid heated thermal cycler
(Bio-Rad, Munich, Germany), started by the initial acti-
vation at 95°C for 15 min. A primer-dependent number
of PCR cycles was consisting of denaturation at 94°C for
30 s, annealing at 55°C for 30 s and elongation at 72°C
for 30 s. PCR-products were analyzed with a CCD cam-
era-equipped UV transilluminator after electrophoresis
in agarose gel.
Immunohistochemistry
At different time points after eMCAO, rats were deeply
anesthezised and the brains were fixed with 4% parafor-
maldehyde (PFA) in 0.1 M phosphate buffer by a transcar-
dial perfusion. Subsequently, the brains were removed,
dissected, postfixed in 4% PFA/PBS overnight at 4°C and
placed in a rat brain matrix (ASI Instruments, Warren,
MI, USA). For the immunohistochemical localisation of
DPIV, DP8 and APN in specific brain cell types, 1 mm
thick coronal brain slices were cut with a razor blade at 14
pre-determined anterior-posterior levels comprising the
cortical infarct area. After cryoprotection with 30%
sucrose, adjacent cryostat sections (20 μm) of each brain
slice were cut in a Cryo-Star HM560M microtome
(Microm International, Walldorf, Germany) and washed
in PBS. Free floating sections were permeabilized in 0.1 M
PBS containing 0.5% Triton X-100 for 30 min followed by
incubation in blocking serum (10% goat normal serum in
0.1 M PBS for 30 min). Subsequently, the sections were
immunostained with the respective primary antibodies, i.e.
monoclonal mouse anti-rat DPIV (OX61, CD26, 1:500;
A b c a m ,C a m b r i d g e ,U K ) ,p o l yclonal rabbit anti-DP8
(1:500; Abcam) or polyclonal rabbit anti-APN (CD13,
1:50; Santa Cruz Biotechnology, Santa Cruz, CA, USA).
For double labeling, these antibodies were incubated
simultaneously with specific cellular markers, i.e. a mono-
clonal mouse anti-neuronal nuclei (NeuN, 1:500, Milli-
pore-Chemicon, Billerica, MA, USA) to identify neurons, a
monoclonal mouse anti-glial fibrilary acid protein (GFAP,
1:200, Molecular Probes, Leiden, The Netherlands) to tar-
get astroglia and a monoclonal mouse anti-rat monocytes/
macrophages (ED1, CD68, 1:500, Millipore-Chemicon) or
IB4-Alexa Fluor 488 (isolectin from Griffonia simlicifolia,
Invitrogen, Darmstadt, Germany)) to label microglia. Tis-
sue sections and antibodies were incubated at 4°C over
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were incubated with fluorescence-labeled secondary anti-
bodies at room temperature for 2 h, i.e. Alexa Fluor 488
goat anti-mouse IgG (1:200; Molecular Probes) and Alexa
Fluor 594 goat anti-rabbit IgG (1:200, Molecular Probes).
In order to reveal the cytoarchitecture of brain sections, a
Nissl staining with Neurotrace fluorescence (Molecular
Probes) was performed. Sections were washed several
times, mounted onto glass slides and embedded with Vec-
tashield containing DAPI to stain nuclei. The specificity of
all antibodies used was assessed by identical immunofluor-
escence staining procedures, with the only exception that
the respective primary antibodies were omitted. Colocali-
sation studies of DPIV, DP8/9 or APN with specific cell
markers were analyzed using a confocal laser scanning
fluorescence microscope (LSM 5 Pascal, Carl Zeiss, Jena,
Germany).
Measurement of DPIV protease activity (H-Gly-Pro-pNA
hydrolysis)
Protease activity measurements were performed in tissue
homogenates freshly prepared from rat cortex. Cortices
from ipsilateral or contralateral hemispheres after
eMCAO or from control animals were separately pre-
pared and analyzed. Animals were sacrificed by cervical
dislocation. Cortices were dissected, wet weight mea-
sured and subsequently, roughly chopped with scissors
and transferred into a tissue potter containing 1 ml PBS
with 1% Triton X-100. The homogenization was per-
formed by rotary and vertical potter movements. The
homogenates were diluted in PBS to a final concentra-
tion of 10 mg wet weight/ml.
Ac o n t i n u o u sf l u o r i m e t r i ca s s a yw a sp e r f o r m e db y
applying distinct concentrations of H-Gly-Pro-pNA as
substrate of DPIV and DPIV-like proteases (DPII, DP8
and DP9). The liberation of p-nitro-aniline (pNA) was
measured in a total volume of 200 μl PBS (10 mM sub-
strate, pH 7.5, Sigma-Aldrich, Taufkirchen, Germany)
containing 80 μl tissue homogenate. The pNA absorp-
tion was measured at 390 nm using a Microplate-Reader
(FluoStar Optima, BMG-Labtech, Offenburg, Germany).
Protease activity, expressed as nmol/min/mg protein,
was calculated using a pNA-standard curve. Protein
concentrations were quantified using the BCA Protein
Assay Kit (Pierce Biotechnology, Rockford, IL, USA).
In general, ipsilateral and contralateral cortices were
analyzed separately at pre-defined time points after
eMCAO. Fractional activities of DPIV and the different
DPIV-like proteases were calculated from protease-spe-
cific inhibitor titration curves that were individually gen-
erated with a selective inhibitor of DPII, DPIV or DP8/9
(final inhibitor concentration 10
-12 Mt o1 0
-3 M) and
Gly-Pro-pNA (400 μM) at pH 7.5 (for details, see
Calculations).
Measurement of APN enzymatic activity (Ala-pNA
hydolysis)
APN and cAAP protease activity was determined using
Ala-pNA (800 μM) as substrate and the same assay con-
ditions as described for DPIV measurements. Competi-
tive inhibition curves were obtained by the adjustment
of increasing concentrations of the specific cAAP inhibi-
tor PAQ22 and the non-selective APN/cAAP inhibitor
actinonin, respectively (final concentration of each inhi-
bitor 10
-12 Mt o1 0
-4 M). The fractional activity of
cAAP in homogenates was calculated from the maxi-
mum PAQ22-inhibited enzyme activity as percent of
total actinonin-sensitive protease activity at pH 7.5.
Calculations
For data analysis, SigmaPlot and SigmaStat software
packages were used (Systat Software, Erkrath, Germany).
The kinetic data analysis was performed using the
Michaelis-Menten-equation. For the analysis of frac-
tional protease activities, subtype-selective inhibitor
titration curves were fitted using the equation for a two-
side competition curve:
y = min+

(max−min) ∗

F1
1+1 0 (x−logIC501)

+

(1 − F1)
1+1 0 (x−logIC502)

IC501I C 50-value of the inhibitor (high affinity
inhibition)
IC502I C 50-value of the inhibitor (low affinity
inhibition)
F1 ratio of inhibition side (high affinity inhibition)
max maximum activity (without inhibition)
min minimum activity (maximum inhibition)
x given inhibitor concentration as decadic log (variable)
y product concentration (dependent variable)
Effect of protease inhibitors on infarct volumes after
eMCAO
In order to perform the icv application of different pro-
tease inhibitors under halothane anesthesia, a second
burr hole was drilled into the skull (coordinates: poster-
ior 0.80 mm from bregma, lateral 1.5 mm to satura
sagittalis). Then, a 29-gauge cannula was lowered 4.5
mm below the dura. The icv injection of IPC1755 (2 μl
of a 10 mmol/l PBS/DMSO solution, pH 7.4, f.c. 10 μM)
was performed according to one of the following time
schedules; (1) during ischemia, 6 and 24 h after
eMCAO, (2) 2, 6, and 24 h after eMCAO and (3) only 6
and 24 h after eMCAO. Sitagliptin as well as DPII- or
DP8/9-specific inhibitors (2 μlo fa1 0m m o l / lP B S /
DMSO solution, pH 7.4, f.c. 10 μM) were administered
exclusively according to schedule 1, i.e. during eMCAO,
6 and 24 h after eMCAO. For controls, vehicle (2 μl)
instead of the corresponding protease inhibitor was
injected. According to legal requirements of the German
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each drug injection. Control rats were treated in the
same way, except that the corresponding vehicle solu-
tion instead of the drug was injected. Thus, potential
protective effects of halothane can be excluded. Rats
were maintained at 37 ± 0.5°C throughout the operation
procedures. In parallel, the body temperature was moni-
tored using a rectal temperature sensor. Subsequently,
the animals were placed into an incubator to maintain
normothermia until recovery from anesthesia and then
returned into their home cage.
After a survival time of 7 days after eMCAO, animals
were anesthetized by intraperitonial injection of pento-
barbital and transcardially perfusion-fixed with saline fol-
lowed by 4% paraformaldehyde in 0.1 M PBS (pH 7.4).
Brains were then removed carefully, post-fixed in the
same fixative for 2 h, and placed in a rodent brain matrix
(rat, ASI Instruments, Warren, MI, USA). 1-mm coronal
brain slices were cut with a razor blade at 14 predeter-
mined anterior-posterior levels. After cryoprotection in
30% sucrose, slices were rapidly frozen in isopentane and
stored at -80°C. Four to five cryostat sections (30 μm)
from each brain slice were cut in a cryo microtome and
stained with toluidine blue.
The extent of cortical and striatal damage following
ischemic injury was documented with microphotographic
images from Nissl-stained slices showing the anterior-pos-
terior level according to the brain atlas of Paxinos and
Watson [34]. The volumes of cortical and striatal infarct
lesions were measured at eight predetermined anterior-
posterior levels by an operator blinded to the group com-
position. Three-dimensional lesion sizes were calculated
by integration of two-dimensional lesion sizes at each
stereotactic level and the distances between the various
levels. Image analysis was performed with an Eclipse TE
3000 microscope (Nikon, Düsseldorf, Germany), equipped
with a 4x objective, and the Lucia software package (Ver-
sion 4.2.1., Nikon). Data were statistically analyzed by
non-paired Student’s t-test and given as mean ± S.E.M.
Statistical significance was defined at p values < 0.001 or
p < 0.01 as indicated.
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